Alpha-2 agonist polymeric drug delivery systems
AssigneeAllergan, Inc.
InventorsJames Chang, Lon Spada, Wendy Blanda, Werhner Orilla, James Burke, Patrick Hughes
Life of this patent
Estimating the term…
Loading patent…
AssigneeAllergan, Inc.
InventorsJames Chang, Lon Spada, Wendy Blanda, Werhner Orilla, James Burke, Patrick Hughes
Estimating the term…
Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
A biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist and a biodegradable polymer, wherein the biodegradable polymer comprises an ester end-capped biodegradable polymer and an acid end-capped biodegradable polymer.
A biodegradable intraocular implant comprising:
A process for making a biodegradable intraocular implant comprising:
A method for treating an ocular condition selected from the group consisting of:
A biodegradable intraocular implant comprising a plurality of forms of an alpha-2 adrenergic receptor agonist and a biodegradable polymer.
A biodegradable intraocular implant comprising:
A process for making a biodegradable intraocular implant comprising:
A method for treating an ocular condition selected from the group consisting of:
A method of treating a symptom of glaucoma, the method comprising the step of placing a biodegradable intraocular implant comprising an alpha-2 adrenergic receptor agonist associated with a biodegradable polymer into the vitreous of an eye, thereby treating a symptom of the glaucoma.
A biodegradable intraocular implant comprising about 12% brimonidine tartrate, about 78 wt % PLA, and about 10 wt % PLGA, wherein the PLA is made using two different molecular weight polymers.
A process for making a biodegradable intraocular implant comprising:
A non-biodegradable intraocular implant comprising a plurality of forms of an alpha-2 adrenergic receptor agonist and a non-biodegradable polymer.
Dependencies are inferred from the claim text.